Navigation Links
UL Expands Presence in Medical Device Market With Acquisition of MDT
Date:8/2/2011

NORTHBROOK, Ill. and OCHSENHAUSEN, Germany, Aug. 2, 2011 /PRNewswire/ -- UL, a world leader in advancing safety, today announced that it has acquired mdt medical device testing GmbH (MDT) and md registration support Ltd. (MDRS).  These two entities, based in Ochsenhausen, Germany, will become part of UL's Life and Health business unit.  

MDT is a leading accredited and GLP certified test laboratory for the medical services industry.  MDT specializes in clinical and non-clinical testing services for regulatory and routine control purposes.  Its testing services include clinical investigations as a clinical research organization (CRO) according to ISO 14155, and comprehensive non-clinical testing services such as physico-chemical and chemical analyses, physical testing, mechanical testing, biocompatibility testing, microbiological and virological testing, cytotoxicity testing and validation of cleaning, reprocessing, sterilization and packaging processes.  MDRS's advisory services enable customers to meet comprehensive medical device registration requirements through technical documentation, risk assessment, clinical evaluation, evaluation of biocompatibility, classification of medical devices and quality management assessment pursuant to EN ISO 9011 and EN ISO 13485, respectively.

UL will now offer a complete suite of services that will help medical device manufacturers produce safer devices and products, including key medical device testing.  The tests are conducted in laboratories that produce repeatable test results under and EN ISO/IEC 17205 and GLP/GCP quality management system, which will expose potential patient side effects well before the medical device is in the market.  The addition of MDT and MDRS will further support UL on a global scale to help medical device manufacturers obtain required medical device certification, including IEC 60601-X-X and ISO 10993-XX, as well as technical documen
'/>"/>

SOURCE UL
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
2. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
3. Cellectar Expands Clinical Management Team
4. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
5. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
6. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
7. PAREXEL Expands Global Clinical Pharmacology Capabilities
8. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
9. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
10. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
11. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014 Levi & ... commenced in the United States District Court for the ... of investors who purchased Galectin Therapeutics Inc. ("Galectin" or ... and July 28, 2014. For more information, ... alleges that during the Class Period the Company violated ...
(Date:8/28/2014)... , August 28, 2014 According ... Research "Radiofrequency Identification (RFID) Market (Tags, Readers, Middleware, Printers ... Trends and Forecast, 2014 - 2020" the global radiofrequency ... in 2013 and is expected to grow at a ... an estimated value of USD 5.3 billion in 2020. ...
(Date:8/28/2014)... , Aug. 28, 2014 ... research report is available in its ... in Asia-Pacific Markets to 2020 - ... Need in Newly Diagnosed and Recurrent ... Glioblastoma Multiforme ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 3Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 4Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9
(Date:8/28/2014)... 2014 (HealthDay News) -- Arguments between parents may damage ... Parents in more than 200 families were asked ... the end of each day, mothers and fathers rated ... their children. On days when parents reported conflict ... children were also strained, according to the study recently ...
(Date:8/28/2014)... 28, 2014 Biotronic, a Great Point ... neurophysiology monitoring ("IONM") company, today announced the promotion of ... Chief Executive Officer effective immediately. Mr. Gecsey joined Biotronic ... CFO in 2013 and has been an integral part ... efforts and achievements since joining the company in 2010 ...
(Date:8/28/2014)... 28, 2014 Bank lending to the private ... down by 0.13% in real terms, and continuing to fall ... study by UHY, the international accountancy network. , UHY warns ... in particular, the credit crunch lingers on. , UHY says ... last year have been wiped out by inflation. Over the ...
(Date:8/28/2014)... fermentation," when yeast that should be busily converting grape ... leaving the remaining sugar to instead be consumed by ... of researchers including UC Davis yeast geneticist Linda Bisson ... Working through a prion -- an abnormally shaped ... bacteria in fermenting wine to switch yeast from sugar ...
(Date:8/28/2014)... In 2012, The Ben & Catherine Ivy ... groundbreaking brain cancer research projects at the Translational ... has officially received the final regulatory approval from ... enrollment for the trial can begin. , In ... Glioblastoma Trial," TGen and its clinical partners will ...
Breaking Medicine News(10 mins):Health News:Parents' Fights May Strain Bonds With Their Kids 2Health News:Biotronic NeuroNetwork Announces the Promotion of Bill Gecsey to CEO 2Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 2Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 3Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 4Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 5Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 6Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 7Health News:Prions can trigger 'stuck' wine fermentations, researchers find 2Health News:TGen receives approval for patient enrollment in brain cancer clinical trial 2
... , TARRYTOWN, N.Y., Nov. 24 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... Annual Piper Jaffray Healthcare Conference on Tuesday, December 1, 2009. ... The session may be accessed through the Company,s web ... An archived version of the presentation will be available after ...
... lead to persistent wheezing, study finds , TUESDAY, Nov. ... pollution and indoor endotoxin are at increased risk for ... bacteria believed to trigger an immune response in humans ... College of Medicine researchers found persistent wheezing (an early ...
... less likely to become disabled, study finds , TUESDAY, ... progression of multiple sclerosis, new research suggests. , Belgian ... symptoms between the ages of 22 and 38. , Women ... 34 percent less likely to have the disease progress to ...
... , SHANGHAI, Nov. 24 /PRNewswire-Asia/ ... in China, is proud to announce,that the company received the ... to the top 100 private technology companies in the Asia ... Technology Fast 100 list every year for various,regions, such as ...
... , TEL-AVIV, ... chemicals company, today reported,results for the third quarter and nine ... Financial Results for the Third Quarter , ... $1,347 million, up,24% as compared sequentially with $1,083 million for ...
... ... media to interact with patients and share information about his North Carolina plastic surgery ... ... surgeon Dr. Richard Cummings has joined the popular social networking site Facebook to expand ...
Cached Medicine News:Health News:Traffic, Dust Linked to Asthma in Kids 2Health News:Childbirth May Slow Progression of Multiple Sclerosis 2Health News:Childbirth May Slow Progression of Multiple Sclerosis 3Health News:Sundia MediTech Receives Red Herring Asia Top 100 Award 2Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 2Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 3Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 4Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 5Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 6Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 7Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 8Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 9Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 10Health News:North Carolina Plastic Surgeon Embracing Social Media to Connect with Patients and Reach Out to Community 2Health News:North Carolina Plastic Surgeon Embracing Social Media to Connect with Patients and Reach Out to Community 3
The Biopro All Poly cup is a uniquely designed UHMWPE acetabular cup....
The Pe-Plus offers an additional clinical option for replacing the acetabulum....
BatCup cotyloid implant, designed for use in revision surgery, is an hemispherical metal cup, with grooves on the edges that house locking flanges, which are attached to the iliac bone by cancellous ...
The cementless acetabular shells form part of the Mallory head range of femoral and acetabular implants....
Medicine Products: